Merck to Hold Fourth-Quarter and Full-Year 2020 Sales and Earnings Conference Call on February 4
January 08 2021 - 06:45AM
Business Wire
Merck (NYSE: MRK), known as MSD outside the United States and
Canada, will hold its fourth-quarter and full-year 2020 sales and
earnings conference call with institutional investors and analysts
at 8:00 a.m. EST on Thursday, Feb. 4. During the call, company
executives will provide an overview of Merck’s performance for the
quarter.
Investors, journalists and the general public may access a live
audio webcast of the call on Merck’s website at
https://www.merck.com/investor-relations/events-and-presentations/.
A replay of the webcast, along with the sales and earnings news
release, presentation and supplemental financial disclosures, will
be available at www.merck.com.
Institutional investors and analysts can participate in the call
by dialing (833) 353-0277 or toll free (469) 886-1947 and using ID
code number 2268598. Members of the media are invited to monitor
the call by dialing (833) 353-0277 or toll free (469) 886-1947 and
using ID code number 2268598. Journalists who wish to ask questions
are requested to contact a member of Merck’s Media Relations team
at the conclusion of the call.
About Merck
For more than 125 years, Merck, known as MSD outside of the
United States and Canada, has been inventing for life, bringing
forward medicines and vaccines for many of the world’s most
challenging diseases in pursuit of our mission to save and improve
lives. We demonstrate our commitment to patients and population
health by increasing access to health care through far-reaching
policies, programs and partnerships. Today, Merck continues to be
at the forefront of research to prevent and treat diseases that
threaten people and animals – including cancer, infectious diseases
such as HIV and Ebola, and emerging animal diseases – as we aspire
to be the premier research-intensive biopharmaceutical company in
the world. For more information, visit www.merck.com and connect
with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
There can be no guarantees with respect to pipeline products that
the products will receive the necessary regulatory approvals or
that they will prove to be commercially successful. If underlying
assumptions prove inaccurate or risks or uncertainties materialize,
actual results may differ materially from those set forth in the
forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of the global outbreak of novel coronavirus disease
(COVID-19); the impact of pharmaceutical industry regulation and
health care legislation in the United States and internationally;
global trends toward health care cost containment; technological
advances, new products and patents attained by competitors;
challenges inherent in new product development, including obtaining
regulatory approval; the company’s ability to accurately predict
future market conditions; manufacturing difficulties or delays;
financial instability of international economies and sovereign
risk; dependence on the effectiveness of the company’s patents and
other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2019
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210108005083/en/
Media: Patrick Ryan (973) 275-7075
Investors: Peter Dannenbaum (908) 740-1037
Michael DeCarbo (908) 740-1807
Merck (NYSE:MRK)
Historical Stock Chart
From Feb 2024 to Mar 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2023 to Mar 2024